Semapimod clinical trials
Also written CNI-1493.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How each study uses semapimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses semapimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's DiseaseCompletedPhase 2Ferring PharmaceuticalsNCT00740103Written as Semapimod
- Extension Study of Semapimod 60 mg IV x 3 DaysCompletedPhase 2Ferring PharmaceuticalsNCT00741910Written as Semapimod
- Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus PlaceboCompletedPhase 2Ferring PharmaceuticalsNCT00739986Written as Semapimod
- CNI-1493 for Treatment of Moderate to Severe Crohn's DiseaseTerminatedPhase 2Ferring PharmaceuticalsNCT00038766Written as semapimod
Codes
What other systems call semapimod · ClinicalTrials.gg INT003882
- MeSH (NLM) C097256semapimodConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9SGW2H1K8PSEMAPIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q7449117semapimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96535SemapimodOne source FDA
- DrugBank DB12094One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C097256 | semapimod | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9SGW2H1K8P | SEMAPIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7449117 | semapimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96535 | Semapimod | One source FDA |
| DrugBank | DB12094 | — | One source Wikidata |
Also registered as semapimod hydrochloride dihydrate (UNII 49H2LZA8OM), semapimod mesylate (UNII 8W415THB21) and semapimod tetrahydrochloride (UNII A16WYQ522A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.